Article Image

IPFS News Link • Science, Medicine and Technology

A startup that just launched out of stealth a few months ago thinks it's found a way to....

• http://www.businessinsider.com, Lydia Ramsey

Stemcentrx, a startup with backing from Silicon Valley investors including Artis Ventures and Founders Fund, was just acquired by AbbVie for $5.8 billion in cash and stock.

But the startup's investors could get up to $4 billion more if Stemcentrx hits successful milestones for clinical developments. Plus the company had about $400 million in the bank. So all in, it's about a $10.2 billion deal.

Stemcentrx is researching drugs designed to treat cancer by targeting cancer stem cells with the intent to attack those cells to keep the cancer from spreading. Unlike general adult stem cellsthat are found all over the body as unspecified cells that are good at regenerating, cancer stem cells are a specific type of cancer cell that some research suggests could play a key role in defeating the disease.


Free Talk Live